Differential effects of the tumor necrosis factor alpha-blocker infliximab and etanercept on immunocompetent cells in vitro-Reference-Cited by-同舟云学术

Differential effects of the tumor necrosis factor alpha-blocker infliximab and etanercept on immunocompetent cells in vitro

Published:2011-11 Issue:11 Volume:11 Page:1724-1731
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Thaher Firas,Plankenhorn Sandra,Klein Reinhild

Funder

Deutsche Forschungsgemeinschaft, Bonn Bad Godesberg

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference63 articles.

1. The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk;Popa;J Lipid Res,2007

2. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review;Tracey;Pharmacol Ther,2008

3. Differences between anti-tumor necrosis factor-a monoclonal antibodies and soluble TNF receptors in host defense impairment;Dinarello;J Rheumatol,2005

4. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned;Reinhart;Crit Care Med,2001

5. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?;Feldmann;Annu Rev Immunol,2001

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease;Frontiers in Immunology;2021-03-09

2. The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells;Neoplasia;2019-07

3. IgG4 anti-infliximab in treated patients: Clinical impact and temporal evolution;Allergy;2018-10-02

4. Biological Agents in Rheumatoid Arthritis: A Cross-Link Between Immune Tolerance and Immune Surveillance;Current Rheumatology Reviews;2018-07-06

5. Sulphite oxidase (SO) – a mitochondrial autoantigen as target for humoral and cellular immune reactions in primary sclerosing cholangitis;BMC Gastroenterology;2018-05-02